Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$111.81
+0.9%
$107.76
$28.66
$126.38
$11.98B0.45851,884 shs668,636 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$22.87
-0.6%
$24.43
$18.22
$27.98
$11.49B1.684.57 million shs7.03 million shs
Hypermarcas stock logo
HYPMY
Hypermarcas
$4.50
-1.1%
$4.20
$3.71
$5.50
$3.20B0.714,943 shs3,599 shs
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
$58.00
$58.00
$55.88
$60.00
$11.97B0.251 shsN/A
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
-0.88%-2.77%-3.19%+35.56%+59.38%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-0.57%-3.86%-2.60%-1.41%+23.62%
Hypermarcas stock logo
HYPMY
Hypermarcas
+0.22%+2.18%+8.95%+11.78%+7.67%
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
0.00%0.00%0.00%-3.33%-11.37%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$111.81
+0.9%
$107.76
$28.66
$126.38
$11.98B0.45851,884 shs668,636 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$22.87
-0.6%
$24.43
$18.22
$27.98
$11.49B1.684.57 million shs7.03 million shs
Hypermarcas stock logo
HYPMY
Hypermarcas
$4.50
-1.1%
$4.20
$3.71
$5.50
$3.20B0.714,943 shs3,599 shs
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
$58.00
$58.00
$55.88
$60.00
$11.97B0.251 shsN/A
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
-0.88%-2.77%-3.19%+35.56%+59.38%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-0.57%-3.86%-2.60%-1.41%+23.62%
Hypermarcas stock logo
HYPMY
Hypermarcas
+0.22%+2.18%+8.95%+11.78%+7.67%
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
0.00%0.00%0.00%-3.33%-11.37%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
2.50
Moderate Buy$138.1723.57% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$29.0927.20% Upside
Hypermarcas stock logo
HYPMY
Hypermarcas
3.00
BuyN/AN/A
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest HYPMY, CORT, RCDTF, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
DowngradeHold (C)Hold (C-)
9/4/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
UpgradeSell (D)Sell (D+)
8/20/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
UpgradeHold (C-)Hold (C)
8/20/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
DowngradeSell (D+)Sell (D)
8/18/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Initiated CoverageBuy$164.00
8/6/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetBuy$31.00 ➝ $33.00
8/6/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetOverweight$29.00 ➝ $30.00
7/31/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
UpgradeSell (D)Sell (D+)
7/30/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Boost Price TargetBuy$95.00 ➝ $165.00
7/30/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Reiterated RatingOverweight$88.00 ➝ $165.00
7/29/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Boost Price TargetBuy$135.00 ➝ $150.00
(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$761.41M15.87$0.91 per share122.76$6.16 per share18.15
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.42$2.31 per share9.91$13.18 per share1.74
Hypermarcas stock logo
HYPMY
Hypermarcas
$1.38B2.30$0.47 per share9.63$3.54 per share1.27
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
$2.96B4.04N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$99.65M$0.42266.2232.50N/A6.52%8.26%6.45%11/4/2026 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.41N/A17.731.64-3.96%8.13%3.99%11/6/2026 (Estimated)
Hypermarcas stock logo
HYPMY
Hypermarcas
$213.10M$0.509.007.14N/A19.77%12.68%6.78%11/11/2026 (Estimated)
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
$501.92M$2.8020.68N/AN/A18.38%33.73%12.76%11/10/2026 (Estimated)

Latest HYPMY, CORT, RCDTF, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Hypermarcas stock logo
HYPMY
Hypermarcas
$0.13$0.14+$0.01$0.14$452.49 millionN/A
8/5/2026Q2 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.2692$0.34+$0.0708$0.11$1.31 billion$1.37 billion
7/29/2026Q2 2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.0243$0.36+$0.3357$0.36$221.15 million$256.15 million
7/29/2026Q2 2026
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
N/A$0.91N/A$0.65N/A$810.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Hypermarcas stock logo
HYPMY
Hypermarcas
$0.132.88%N/A26.00%N/A
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/A
2.86
2.77
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.58
2.05
1.10
Hypermarcas stock logo
HYPMY
Hypermarcas
0.50
1.86
1.26
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
0.79
1.26
0.86
CompanyEmployeesShares OutstandingFree FloatOptionable
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
730108.10 million85.72 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.62 million493.93 millionOptionable
Hypermarcas stock logo
HYPMY
Hypermarcas
10,481704.01 millionN/ANot Optionable
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
4,693206.30 millionN/ANot Optionable

Recent News About These Companies

BioGaia signe un accord de distribution avec Recordati
Recordati, che fare con l’opa da 10,7 miliardi di Cvc?
Recordati, il cda approva l’Opas di Respighi
Opa Recordati, il cda si spacca sul prezzo
CVC consortium tables $12.4bn bid to delist Italian drugmaker Recordati

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Corcept Therapeutics stock logo

Corcept Therapeutics NASDAQ:CORT

$111.81 +0.99 (+0.89%)
Closing price 04:00 PM Eastern
Extended Trading
$112.11 +0.30 (+0.27%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$22.87 -0.13 (-0.56%)
Closing price 03:59 PM Eastern
Extended Trading
$22.86 -0.01 (-0.03%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Hypermarcas stock logo

Hypermarcas OTCMKTS:HYPMY

$4.50 -0.05 (-1.08%)
As of 03:58 PM Eastern

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

Recordati Industria Chimica E Farmaceutica stock logo

Recordati Industria Chimica E Farmaceutica OTCMKTS:RCDTF

$58.00 0.00 (0.00%)
As of 09/15/2026

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.